Hormonal
Tirzepatide demonstrates superior weight reduction compared to Semaglutide 2.4 mg and significant MASH resolution in patients with histologically-proven MASH.
Tirzepatide is a once-weekly injection for diabetes and obesity that also shows strong promise for treating MASH. It reduces liver fat and inflammation significantly, with higher doses showing better results. It also leads to greater weight loss than Semaglutide in head-to-head comparisons.
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, has demonstrated superiority to Semaglutide 2.4 mg in head-to-head comparisons of weight reduction... In the SYNERGY-NASH trial... resolution of MASH occurred in a dose-dependent manner in 44% (5 mg), 56% (10 mg), and 62% (15 mg) of Tirzepatide patients vs. 10% in the placebo arm
Why this rating
Based on Phase 2 trial (SYNERGY-NASH) and head-to-head weight loss comparisons.
Source
AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update
Alessio Aghemo et al. · Digestive and Liver Disease · 2026
DOI 10.1016/j.dld.2026.02.014
More from this paper
- Resmetirom (80-100 mg daily) improves histological MASH resolution and fibrosis in patients with F2-F3 fibrosis without requiring significant weight loss, while also lowering LDL cholesterol.Strong
- Semaglutide (2.4 mg weekly) significantly improves MASH resolution and fibrosis in patients with F2-F3 fibrosis, with benefits extending to significant weight loss and metabolic improvements.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →